AstraZeneca

A new drug that significantly lowers "stubborn" blood pressure is on the horizon, following the results of its Phase III clinical trial. The drug, called baxdrostat, is being hailed as the most promising advance in hypertension management in decades.

Game-changing GLP-1 agonist drugs are a step closer to being available in oral pill form, with AstraZeneca revealing "encouraging data" from the Phase I safety and tolerability trial of its once-daily obesity and diabetes drug AZD5004.

A man that police caught taking 217 doses of COVID vaccine has offered himself up to researchers for a study looking into what happens to the immune system after so many doses. The results offer surprising insight into these new mRNA vaccines.

Designs have been released for AstraZeneca's planned new corporate HQ and global R&D center in Cambridge, UK. The facility will cost around £330 million (US$560 million). Designed by Herzog & de Meuron, it will include high-tech research spaces, collaboration spaces and a green, low-energy design.